AperçuGraphiqueActualitésTraderScreen

Morgan Stanley Discount Zert REGN.../  DE000MG45M19  /

Stuttgart
07/11/2024  13:52:53 Chg.+0.04 Bid14:44:20 Demandez à14:44:20 Sous-jacent Prix d'exercice Date d'expiration Type d'option
74.33EUR +0.05% 74.08
Bid taille: 300		 74.55
Ask la taille: 300		 Regeneron Pharmaceut... - USD 30/12/2025 Call
GlobeNewswire 28/08 Kiniksa Pharmaceuticals to Present at 2024 Wells Fargo Healthcare Conference
GlobeNewswire 26/08 Ordspono™ (odronextamab) Approved in the European Union for the Treatment of Relapsed/Refractory Fol...
GlobeNewswire 26/08 Latest Dupixent® (dupilumab) and Itepekimab Data at ERS Highlight Scientific Innovation and Leadersh...
GlobeNewswire 21/08 Regeneron Provides Update on Biologics License Application for Linvoseltamab
GlobeNewswire 15/08 Alvotech Reports Record Revenues and Adjusted EBITDA for the Second Quarter and First Six Months of ...
GlobeNewswire 15/08 European Medicines Agency Confirms Acceptance of Marketing Application for AVT06, a Proposed Biosimi...
GlobeNewswire 12/08 Sandoz receives FDA approval for Enzeevu™ (aflibercept-abzv), further strengthening US biosimilar po...
GlobeNewswire 08/08 Intellia Therapeutics Announces Second Quarter 2024 Financial Results and Highlights Recent Company ...
GlobeNewswire 07/08 Regeneron Announces Investor Conference Presentations and Oncology Investor Webcast
GlobeNewswire 05/08 BioNTech Announces Second Quarter 2024 Financial Results and Corporate Update
GlobeNewswire 01/08 Regeneron Reports Second Quarter 2024 Financial and Operating Results
GlobeNewswire 31/07 Regeneron Announces the 2024 Winners of the Regeneron Prize for Creative Innovation
GlobeNewswire 23/07 Kiniksa Pharmaceuticals Reports Second Quarter 2024 Financial Results and Recent Portfolio Execution
GlobeNewswire 23/07 BridgeBio Announces Appointment of Thomas Trimarchi, Ph.D., as President and Chief Operating Officer
GlobeNewswire 16/07 Kiniksa Pharmaceuticals to Report Second Quarter 2024 Financial Results on July 23, 2024
GlobeNewswire 10/07 Regeneron Pharmaceuticals, Inc. Investors: Company Investigated by the Portnoy Law Firm
GlobeNewswire 07/07 SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharma...
GlobeNewswire 03/07 Dupixent® (dupilumab) Approved in the European Union as the First-ever Targeted Therapy for Patients...
GlobeNewswire 03/07 Press Release: Dupixent approved in the EU as the first-ever targeted therapy for patients with COPD
GlobeNewswire 30/06 SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharma...
GlobeNewswire 28/06 Odronextamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Follicular Lymphom...
GlobeNewswire 27/06 Regeneron to Report Second Quarter 2024 Financial and Operating Results and Host Conference Call and...
GlobeNewswire 26/06 Dupixent® (dupilumab) Positive Phase 3 Data in Children 1 to 11 Years of Age with Eosinophilic Esoph...
GlobeNewswire 26/06 Press Release: Dupixent positive phase 3 data in children one to 11 years of age with eosinophilic e...
GlobeNewswire 22/06 SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharma...